The autoimmune diseases as the illness Addison’s disease, celiac disease, dermatomyositis, Graves disease, Hashimoto’s thyroiditis, myasthenia gravis, multiple sclerosis, rheumatoid arthritis, Sjogren’s syndrome, lupus systemic erythematosus and type 1 diabetes and finally the fibromyalgia than a recent study coordinated by prof. Claudio Lunardi, of the Department of Medicine of the University of Verona, and by prof. Antonio Puccetti, of the Department of Experimental Medicine of the University of Genoa, ha detected the existence of an autoimmune component, they have an inflammatory condition at the base.
In a long-term collaboration between researchers and the pharmaceutical industry, it has been accomplished a significant first step in creating a new generation of autoimmune disease drugs using one of our body’s anti-inflammatory quenching molecules.
THE results of the research collaboration were published in the scientific journal Cell Chemical Biology.
Autoimmune diseases: a step forward in the search for effective drug therapies
The immune system produces many very powerful anti-inflammatory molecules, but they are often fragile, short-lived, and lacking in drug-like properties. Interleukin-37 it is one of these molecules produced by the body to quench inflammation.
Together with partner F. Hoffmann-La Roche (Roche), the multidisciplinary research team of Hudson Institute of Medical Research, Monash University Biomedicine Discovery Institute (BDI) and Monash University Department of Pediatrics leveraged their Fc-fusion platform to design the next generation of Interleukin-37, a molecule that retains anti-inflammatory potency, is highly stable, and has excellent therapeutic function.
The associate professor Claudia Nold at theHudson Institute of Medical Research, one of the leading scientists, states that: “Working in the field of inflammation, we have been delighted to partner with Roche, a Swiss healthcare pioneer since 1896. Our collaboration between academia, physicians and industrial partners such as Roche has enabled us to leverage our combined expertise and solve biomedical issues to take a step forward in the development of innovative drugs for patients with inflammatory autoimmune diseases ”.
A little inflammation can sometimes be a good sign and often it’s the body’s immune system doing its job. However, when the inflammation persists or the immune system begins to attack the cells of the body, this can lead to serious illness. This research aims to create a new generation of drugs for autoimmune diseases.
Another of the study’s lead authors, Dr. Andrew Ellisdon of the Monash BDI, states that many human diseases, including autoimmune conditions such asarthritis, the lupus or le inflammatory bowel diseases, are characterized by excessive inflammation. Ellisdon says there has been a gap in the production of new generations of powerful anti-inflammatory therapies for these anti-inflammatory conditions.
“The past five years have been a tremendous opportunity to collaborate and learn from Roche, a world leader in the engineering and development of biologics. Thanks to the data from this study, we now know how to make more stable and medical-like versions of the body’s anti-inflammatory switches “, said the specialist.
“This study builds a robust platform for testing IL-37-based Fc fusion variants in a range of preclinical models of autoimmune and inflammatory diseases. We anticipate that many of the steps taken in this Fc engineering platform will be broadly applicable to other difficult and unstable biologics“, has continued Ellisdon.
Professor Marcel Nold, professor of pediatric immunology at the Monash University and consultant in neonatal pediatrician at the Monash Children’s Hospital, he has declared: “The ultimate goal of a clinical scientist is to be part of the research that can be translated into future treatments for patients ”.
Autoimmune diseases are a condition where the immune system mistakenly attacks its own body. The immune system normally protects against pathogens such as bacteria and viruses. When it detects these foreign invaders, it dispatches an army of fighting cells to attack them. Normally, the immune system can distinguish between foreign cells and its own cells.
In an autoimmune disease, the immune system “decodes” a part of the body, such as the joints or skin, as foreign. It releases proteins called autoantibodies that attack healthy cells. Some autoimmune diseases affect only one organ. The type 1 diabetes for example it damages the pancreas. Other diseases, such as systemic lupus erythematosus (SLE), they affect the whole body.
To date, the scientific community does not know exactly what causes the immune system to ignite irregularly. However, some people are more likely to get an autoimmune disease than others. According to one 2014 study , women contract autoimmune diseases at a rate of about 2 to 1 compared to men: 6.4 percent of women versus 2.7 percent of men. Often the disease begins during a woman’s childbearing age (15 to 44 years).
Some autoimmune diseases are more common in some ethnic groups. For example, lupus affects more African American and Hispanic people than Caucasians. Other autoimmune diseases, such as multiple sclerosis and lupus, are familiar. Not all family members will necessarily have the same disease, but they will inherit a predisposition to an autoimmune condition.
As the incidence of autoimmune diseases is on the rise, researchers suspect that environmental factors such as infections and exposure to chemicals or solvents may also be involved.
One ” western diet Is another suspected risk factor for developing an autoimmune disease. Eating foods high in fat, sugar and highly processed is thought to be linked to inflammation, which could trigger an immune response. However, this has not been proven.
#Autoimmune #Diseases #Inflammation #extinguished